Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Next Previous
Trial Profile

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Generalised seizures; Partial epilepsies; Seizures
  • Focus Adverse reactions
  • Acronyms BRITE
  • Sponsors UCB

    • Most Recent Events

    • 01 Jan 2023 Results of post hoc analysis evaluating long-term retention, reasons for discontinuation, efficacy, tolerability, and health-related quality of life (HRQOL) during adjunctive brivaracetam (BRV) treatment in adults with focal seizures by number of lifetime antiseizure medications published in the Epilepsy and Behavior
    • 01 May 2021 Results reporting efficacy outcomes up to 36 months published in the Epilepsy and Behavior
    • 08 Dec 2020 Results of post hoc analysis evaluating the long-term retention, reasons for discontinuation, efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal seizures by number of lifetime antiepileptic drugs (AEDs). presented at the 74th Annual Meeting of the American Epilepsy Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top